美银证券最新发布的研究报告显示，石药集团（01093）今年上半年总收入及应占净利润分别同比增长40.1%和139.2%，达到186亿元人民币和61亿元人民币。
仅就第二季度而言，该集团总收入同比攀升93.8%至121亿元人民币，应占净利润同比大幅增长389.3%至52亿元人民币。
基于上述业绩表现，美银证券将石药集团2026至2028年的净利润预测分别上调1.9%、2.6%和1.6%，并将目标价从7.6港元提高至8.6港元。
然而，由于核心药物恩必普（NBP）面临价格下调压力，该行决定重申对石药集团的“跑输大市”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.